Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab

Scandinavian Journal of Infectious Diseases

Volumn 39, Issue 5, 2007, Pages 475-478

  Kalyoncu, Umut ^a   Karadag, Omer ^a   Akdogan, Ali ^a   Kisacik, Bunyamin ^a   Erman, Mustafa ^a   Erguven, Sibel ^a   Ertenli, A Ihsan ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; COTRIMOXAZOLE; DEFLAZACORT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; LEVOFLOXACIN; METHOTREXATE; OXYGEN; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; COMORBIDITY; COUGHING; DISEASE ACTIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; EYE TOXICITY; FEMALE; FEVER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; HYPOXIA; IMMUNOREGULATION; INFECTION RISK; LUNG INFILTRATE; LUNG LAVAGE; OLIGOPHRENIA; OXYGEN THERAPY; PATHOPHYSIOLOGY; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; RHEUMATOID ARTHRITIS; TACHYCARDIA; TACHYPNEA; THORAX RADIOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248174415     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540601071867     Document Type: Article

References (9)

1. Botsios, C. (2005) Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmunity Reviews, 4, pp. 162-170.
2. Sritangratanakul, S., Nuchprayoon, S. and Nuchprayoon, I. (2004) Pneumocystis pneumonia: An update. J Med Assoc Thai, 87, pp. 309-317.
3. Cunnane, G., Doran, M. and Bresnihan, B. (2003) Infections and biological therapy in rheumatoid arthritis. Best Practice and Research Clinical Rheumatology, 17, pp. 345-363.
4. Bakhel, M., Tleyjeh, I., Matteson, E.L and Osmon, D.R. (2005) Infectious compilications of tumour necrosis factor-α antagonists. International Journal of Dermatology, 44, pp. 443-448.
5. Velayos, F. and Sandborn, W.J. (2004) Pneumocystis carinii pneumonia during maintenance anti-tumour necrosis factor-α therapy with infliximab for Crohn's disease. Inflamm Bowel Dis, 10, pp. 657-660.
6. Tai, TL, O'Rourke, KP, McWeeney, M., Burke, CM, Sheehan, K. and Barry, M. (2002) Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology, 41, pp. 951-952.
7. Chen, W., Havell, EA and Harmsen, AG. (1992) Importance of endogenous tumour necrosis factor-alpha and gamma interferon in host resistance against Pneunocystis carinii infection. Infection and Immunity, 4, pp. 1279-1284.
8. Furst, DE, Schiff, MH, Fleischmann, RM, Strand, V., Birbara, CA and Compagnone, D. (2003) Adalimumab, a fully human anti-tumour necrosis factor-alpha monoclonal antibody,and concomitant standard anti-rheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol, 30, pp. 2563-2571.
9. Krebs, S. and Gibbons, RB. (1996) Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia. Mil Med, 161, pp. 58-60.